扶正排毒片对无症状HIV感染者免疫功能调节的研究
|
摘要
目的：以无症状HIV感染期为切入点,通过临床研究,探讨扶正排毒片的临床疗效,在此基础上通过测定相关免疫因子浓度,探讨扶正排毒片对无症状HIV感染者免疫功能的调节作用,观察是否存在免疫因子的差异及相关性,为临床诊断和治疗奠定基础,最终为无症状HIV感染者提供可以增强免疫、延缓发病进程的中药。
方法：本研究分两部分进行。第一部分理论研究,从无症状HIV感染期称谓的由来及此称谓带来的歧义、无症状HIV感染期有症状、无症状HIV感染期有证可辨、中医药治疗艾滋病选择无症状HIV感染期的依据、无症状HIV感染期的中医药治疗进展、基于病因病机辨证治疗无症状HIV感染者共六个方面进行探讨。第二部分运用随机整群抽样、单盲平行对照研究方法,以临床症状、体征、免疫学指标(CD4+、CD8+细胞数以及CD4+/CD8+)、病毒载量、生存质量、血尿便常规、肝肾功能等为观察指标,选择符合入选标准的治疗组56例,对照组52例进行扶正排毒片对无症状HIV感染者的早期干预治疗。在此基础上运用流式细胞术、逆转录-聚合酶链反应(RT-PCR)、酶联免疫吸附试验法对疗效较好的32例进行CD4+、病毒载量及白细胞介素6、白细胞介素8、可溶性白细胞介素2受体、肿瘤坏死因子α、新喋呤、干扰素α浓度的测定,观察是否存在细胞因子的差异及相关性,探讨扶正排毒片对无症状HIV感染者免疫指标的调节作用。
结果：
1无症状HIV感染期有症状并且有证可辨,基于病因病机辨证的治疗为扶正排毒片对无症状HIV感染者的干预提供理论依据。
2扶正排毒片对无症状HIV感染者的疗效研究显示：两组治疗后对无症状HIV感染者的症状体征总积分在a=0.05水准上具有统计学意义(P<0.05),治疗组的有效率和显效人数均明显高于对照组；两组治疗前后CD4+计数的变化没有统计学意义(P>0.05),但以CD4+计数上升或下降50/mm3为评定值计算有效率,两组治疗前和疗后6个月、疗后12个月的CD4+疗效比较均具有统计学意义(P<0.05),疗前和疗后3个月、疗后9个月的CD4+疗效比较没具有统计学意义(P>0.05),但治疗组的有效率明显高于对照组。随机抽取34例(总病例数的1/3,治疗组20例,对照组14例)无症状HIV感染者进行病毒载量检测,与疗前对比,两组疗后6个月和疗后12个月病毒载量疗效的差异在a=0.05水准上没有统计学意义(P>0.05),但治疗组的有效率高于对照组；两组治疗前后病毒载量变化的差异在a=0.05水准上没有统计学意义(P>0.05),但治疗组的病毒载量均数下降较多。通过扶正排毒片干预前后感染者生存质量量表分析,两组治疗前后对精力纬度、情感纬度、疼痛纬度、睡眠纬度积分在a=0.05水准上具有统计学意义(P<0.05),对躯体活动纬度、社会生活纬度积分疗后没有统计学意义(P>0.05),但疗后治疗组躯体活动纬度和社会生活纬度的积分较治疗前明显下降,且低于对照组的积分。扶正排毒片治疗前后安全性指标结果提示：未发现有肝肾功能的损害,未发现对血尿粪常规的不良影响,在临床上也未发现心电图、胸透的不良反应。
3基于免疫激活相关分子的扶正排毒片干预无症状HIV感染者免疫调节机制研究显示：扶正排毒片治疗6个月后,无症状HIV感染者的IL-6、IL-8、TNF-α、NPI、IFN-α水平变化在a=0.05水准上具有统计学意义(P<0.05),而sIL-2R的水平变化在a=0.05水准上没有统计学意义(P>0.05)；无症状HIV感染者疗前IL-8、sIL-2R、TNF-α、NPI、IFN-α水平与健康对照组相比在a=0.05水准上均具有统计学意义(P<0.05),而无症状HIV感染者疗前IL-6水平与健康对照组相比在a=0.05水准上没有统计学意义(P>0.05)；除了TNF-α和IFN-α,各指标内部存在相关性,且呈正相关关系；各指标间NPI疗前与TNF-α疗后、NPI疗后与TNF-α疗后、IFN-α疗前与IL-8疗前、IFN-α疗前与IL-8疗后、CD4+疗前与sIL-2R疗前之间呈负相关关系；各指标间病毒载量疗前与sIL-2R疗前、病毒载量疗前与NPI疗后、病毒载量疗后与NPI疗前、病毒载量疗后与NPI疗后呈正相关系。
结论：
1中医药治疗艾滋病应把无症状HIV感染期作为切入点,针对病因病机辨证治疗。
2扶正排毒片对无症状HIV感染者的症状体征的改善有着较好的效果,具有升高或稳定感染者CD4+计数的趋势,对部分病例具有降低病毒载量的作用,能从不同方面不同程度地提高了感染者的生存质量,临床用药安全。
3本研究表明IL-8、sIL-2R、TNF-α、NPI、IFN-α与无症状HIV感染者密切相关,与其有关的细胞免疫参与其发病的全过程,可以作为了解无症状HIV感染者体内细胞免疫状态、治疗效果及预后判断的重要指标之一。
4各指标内部存在一定相关性,各指标间存在一定相关性,但机制尚不明确,说明在扶正排毒片治疗无症状HIV感染者的作用机制中,上述指标间的关系有待进一步研究。
5本研究表明IL-6、IL-8、TNF-α、NPI、IFN-α对判定中药治疗无症状HIV感染者的疗效有一定意义,可以作为中药疗效判定的参考指标之一。
Objective:With asymptomatic HIV infectious period as the starting point, and through a more standardized clinical study, this research examines the clinical efficacy of Fuzheng Paidu Tablet. Based on this clinical study, we measured the concentration of associated immune factors, discussed the effect of Fuzheng Paidu Tablet in regulating the immune functions of asymptomatic HIV infection Patients, observed whether there are differences and correlation of the immune factor between the two, and established the theoretical foundation for the diagnosis and treatment. Finally we provided asymptomatic HIV carriers with Chinese materia medica preparations that can enhance immunity and delay the occurrence and progress of the disease.
Methods:This research is divided into two parts. The first part is theoretical study. We discussed this from the following six aspects:the origin and ambiguity of asymptomatic HIV infectious period; symptoms in asymptomatic HIV infectious period; TCM symptoms types that can be differentiated in asymptomatic HIV infectious period; the reason of choosing HIV infectious patients in TCM treatment; advances in Chinese medicine treatment during asymptomatic HIV infectious period; treatment of asymptomatic HIV carriers based on etiology, pathogenesis and syndrome differentiation. In the second part cluster random sampling and Single-blind, parallel-group method were used. Outcome measures such as clinical symptoms and signs, immunological indexes (CD4+ cell count, CD8+ cell count and the ratio of CD4+/CD8+), viral load, quality of life, routine analysis of blood, urine and stool, liver Function and kidney function, etc. were observed. Altogether 56 cases in the treatment group met the inclusion criteria, and in the control group 52 cases did. CD4+ cell count, viral load, interleukin-6, interleukin-8, soluble interleukin-2 receptor, tumor necrosis factor-a, neopterin, interferon-a etc of the 32 patients with good clinical effect were measured. Observation was made on whether there are differences and correlation of the cell factor, and discussions were carried out on the moderating effect of Fuzheng Paidu Tablet to the asymptomatic HIV infection Patients' Immunological indexes.
Results:
1 Symptoms existed and TCM symptoms type could be differentiated in asymptomatic HIV infectious period. Treatment of asymptomatic HIV infectious period based on etiology, pathogenesis and syndrome differentiation provided a theoretical foundation for the early intervention of Fuzheng Paidu Tablet to the patients during asymptomatic HIV infectious period.
2 Research on the efficacy of Fuzheng Paidu Tablet to the patients in asymptomatic HIV infectious period indicated that there was statistical significance in the total score after treatment of the two groups at the significance level a=0.05. Effective rate and efficiently individual quantity were higher than that of the control group. There was no statistical significance in the change of CD4+ cell count of the two groups after the treatment. But to calculate the effectiveness by CD4+ cell count increase or decrease by 50/mm3, there is statistical significance between the data before treatment and 6 and 12 months after treatment. However, there was no statistical significance between the data before treatment and 3 and 9 months after treatment, but the efficacy of the treatment group was significantly higher than control group.34 patients in asymptomatic HIV infectious period were randomly selected (1/3 cases of the total number, including 20 patients of the treatment group and 14 patients of the control group) to measure viral load. Compared with the data before treatment, there was no statistical significance in viral load in 6 and 12 months after treatment of the two groups at the significance level a=0.05 (P>0.05), but the efficacy of the treatment was higher than the control group; there was no statistical significance on the change of viral load at the significance level a=0.05 (P>0.05),but the average of the viral load of the treatment group was markedly decreased. Analysis of the quality of life showed that there was statistical significance in the score of energy-latitude, emotional-latitude, pain-latitude, sleep-latitude (P<0.05), there was no statistical significance in the score of physical activity latitude and social life latitude (P> 0.05), but the score of the treatment group was obvious decreased than the score obtained before treatment and lower than the control group. Analysis of the safety indicator of Fuzheng Paidu Tablet found no damage to liver and kidney function, and no adverse effects to routine analysis of blood, urine and stool, and no adverse effects to electrocardiogram and chest X-ray fluoroscopy.
3 The mechanism based on the immune activation related factors of the intervention to the immune regulation of Fuzheng Paidu Tablet showed that after 6 months of treatment, there was statistical significance on the change of IL-6, IL-8, TNF-a, NPI, and IFN-a at the significance level a=0.05(P<0.05), but no statistical significance in sIL-2R (P>0.05). Before treatment there was statistical significance in IL-8, sIL-2R, TNF-a, NPI, and IFN-a compared with the healthy control group (P<0.05), and before treatment, there was no statistical significance in IL-6 compared the healthy control group (P>0.05). Positive correlation exists between each indicator except TNF-αand IFN-α. There was negative correlation between NPI (before treatment) and TNF-α(after treatment), and also negative correlation between fellowing indicators:NPI (after treatment) and TNF-α(after treatment), IFN-α(before treatment) and IL-8 (before treatment), IFN-α(before treatment) and IL-8(after treatment), CD4+ (before treatment) and sIL-2R (before treatment). There was positive correlation between viral load (before treatment) and sIL-2R (before treatment), and also positive correlation between fellowing indicators:viral load (before treatment) and NPI (after treatment), viral load (after treatment) and NPI(before treatment), viral load (after treatment) and NPI (after treatment).
Conclusion:
1 Chinese medicine treatment for HIV/AIDS should take asymptomatic HIV infectious period as the starting point.
2 Fuzheng Paidu Tablet can significantly improve the symptoms and signs of the patients during the asymptomatic HIV infection period, since this has a tendency to increase or stabilize the quantity of CD4 cell, and in some patients it can decrease the viral load, improve the quality of life from different levels and different aspects, and is safe in clinical use.
3 This research suggests that there were close correlation between IL-8, sIL-2R, TNF-a, NPI, IFN-a and the symptom of the asymptomatic HIV infectious period. And cellular immunity correlated to those factors plays an important role in the whole process of the disease, and those factors can be important indicators of the cellular immunity condition and therapeutic effect and prognosis.
4 There were correlations between each indicator, but the mechanism is unknown, and further research is needed on the mechanism of Fuzheng Paidu Tablet in the treatment of the patients during the asymptomatic HIV infection period.
5 This resarch suggest that IL-6, IL-8, TNF-a, NPI, IFN-a have certain significance in determining the efficacy of Fuzheng Paidu Tablet in the treatment of the patients during the asymptomatic HIV infection period. And those factors can serve as important reference indexes.
方法：本研究分两部分进行。第一部分理论研究,从无症状HIV感染期称谓的由来及此称谓带来的歧义、无症状HIV感染期有症状、无症状HIV感染期有证可辨、中医药治疗艾滋病选择无症状HIV感染期的依据、无症状HIV感染期的中医药治疗进展、基于病因病机辨证治疗无症状HIV感染者共六个方面进行探讨。第二部分运用随机整群抽样、单盲平行对照研究方法,以临床症状、体征、免疫学指标(CD4+、CD8+细胞数以及CD4+/CD8+)、病毒载量、生存质量、血尿便常规、肝肾功能等为观察指标,选择符合入选标准的治疗组56例,对照组52例进行扶正排毒片对无症状HIV感染者的早期干预治疗。在此基础上运用流式细胞术、逆转录-聚合酶链反应(RT-PCR)、酶联免疫吸附试验法对疗效较好的32例进行CD4+、病毒载量及白细胞介素6、白细胞介素8、可溶性白细胞介素2受体、肿瘤坏死因子α、新喋呤、干扰素α浓度的测定,观察是否存在细胞因子的差异及相关性,探讨扶正排毒片对无症状HIV感染者免疫指标的调节作用。
结果：
1无症状HIV感染期有症状并且有证可辨,基于病因病机辨证的治疗为扶正排毒片对无症状HIV感染者的干预提供理论依据。
2扶正排毒片对无症状HIV感染者的疗效研究显示：两组治疗后对无症状HIV感染者的症状体征总积分在a=0.05水准上具有统计学意义(P<0.05),治疗组的有效率和显效人数均明显高于对照组；两组治疗前后CD4+计数的变化没有统计学意义(P>0.05),但以CD4+计数上升或下降50/mm3为评定值计算有效率,两组治疗前和疗后6个月、疗后12个月的CD4+疗效比较均具有统计学意义(P<0.05),疗前和疗后3个月、疗后9个月的CD4+疗效比较没具有统计学意义(P>0.05),但治疗组的有效率明显高于对照组。随机抽取34例(总病例数的1/3,治疗组20例,对照组14例)无症状HIV感染者进行病毒载量检测,与疗前对比,两组疗后6个月和疗后12个月病毒载量疗效的差异在a=0.05水准上没有统计学意义(P>0.05),但治疗组的有效率高于对照组；两组治疗前后病毒载量变化的差异在a=0.05水准上没有统计学意义(P>0.05),但治疗组的病毒载量均数下降较多。通过扶正排毒片干预前后感染者生存质量量表分析,两组治疗前后对精力纬度、情感纬度、疼痛纬度、睡眠纬度积分在a=0.05水准上具有统计学意义(P<0.05),对躯体活动纬度、社会生活纬度积分疗后没有统计学意义(P>0.05),但疗后治疗组躯体活动纬度和社会生活纬度的积分较治疗前明显下降,且低于对照组的积分。扶正排毒片治疗前后安全性指标结果提示：未发现有肝肾功能的损害,未发现对血尿粪常规的不良影响,在临床上也未发现心电图、胸透的不良反应。
3基于免疫激活相关分子的扶正排毒片干预无症状HIV感染者免疫调节机制研究显示：扶正排毒片治疗6个月后,无症状HIV感染者的IL-6、IL-8、TNF-α、NPI、IFN-α水平变化在a=0.05水准上具有统计学意义(P<0.05),而sIL-2R的水平变化在a=0.05水准上没有统计学意义(P>0.05)；无症状HIV感染者疗前IL-8、sIL-2R、TNF-α、NPI、IFN-α水平与健康对照组相比在a=0.05水准上均具有统计学意义(P<0.05),而无症状HIV感染者疗前IL-6水平与健康对照组相比在a=0.05水准上没有统计学意义(P>0.05)；除了TNF-α和IFN-α,各指标内部存在相关性,且呈正相关关系；各指标间NPI疗前与TNF-α疗后、NPI疗后与TNF-α疗后、IFN-α疗前与IL-8疗前、IFN-α疗前与IL-8疗后、CD4+疗前与sIL-2R疗前之间呈负相关关系；各指标间病毒载量疗前与sIL-2R疗前、病毒载量疗前与NPI疗后、病毒载量疗后与NPI疗前、病毒载量疗后与NPI疗后呈正相关系。
结论：
1中医药治疗艾滋病应把无症状HIV感染期作为切入点,针对病因病机辨证治疗。
2扶正排毒片对无症状HIV感染者的症状体征的改善有着较好的效果,具有升高或稳定感染者CD4+计数的趋势,对部分病例具有降低病毒载量的作用,能从不同方面不同程度地提高了感染者的生存质量,临床用药安全。
3本研究表明IL-8、sIL-2R、TNF-α、NPI、IFN-α与无症状HIV感染者密切相关,与其有关的细胞免疫参与其发病的全过程,可以作为了解无症状HIV感染者体内细胞免疫状态、治疗效果及预后判断的重要指标之一。
4各指标内部存在一定相关性,各指标间存在一定相关性,但机制尚不明确,说明在扶正排毒片治疗无症状HIV感染者的作用机制中,上述指标间的关系有待进一步研究。
5本研究表明IL-6、IL-8、TNF-α、NPI、IFN-α对判定中药治疗无症状HIV感染者的疗效有一定意义,可以作为中药疗效判定的参考指标之一。
Objective:With asymptomatic HIV infectious period as the starting point, and through a more standardized clinical study, this research examines the clinical efficacy of Fuzheng Paidu Tablet. Based on this clinical study, we measured the concentration of associated immune factors, discussed the effect of Fuzheng Paidu Tablet in regulating the immune functions of asymptomatic HIV infection Patients, observed whether there are differences and correlation of the immune factor between the two, and established the theoretical foundation for the diagnosis and treatment. Finally we provided asymptomatic HIV carriers with Chinese materia medica preparations that can enhance immunity and delay the occurrence and progress of the disease.
Methods:This research is divided into two parts. The first part is theoretical study. We discussed this from the following six aspects:the origin and ambiguity of asymptomatic HIV infectious period; symptoms in asymptomatic HIV infectious period; TCM symptoms types that can be differentiated in asymptomatic HIV infectious period; the reason of choosing HIV infectious patients in TCM treatment; advances in Chinese medicine treatment during asymptomatic HIV infectious period; treatment of asymptomatic HIV carriers based on etiology, pathogenesis and syndrome differentiation. In the second part cluster random sampling and Single-blind, parallel-group method were used. Outcome measures such as clinical symptoms and signs, immunological indexes (CD4+ cell count, CD8+ cell count and the ratio of CD4+/CD8+), viral load, quality of life, routine analysis of blood, urine and stool, liver Function and kidney function, etc. were observed. Altogether 56 cases in the treatment group met the inclusion criteria, and in the control group 52 cases did. CD4+ cell count, viral load, interleukin-6, interleukin-8, soluble interleukin-2 receptor, tumor necrosis factor-a, neopterin, interferon-a etc of the 32 patients with good clinical effect were measured. Observation was made on whether there are differences and correlation of the cell factor, and discussions were carried out on the moderating effect of Fuzheng Paidu Tablet to the asymptomatic HIV infection Patients' Immunological indexes.
Results:
1 Symptoms existed and TCM symptoms type could be differentiated in asymptomatic HIV infectious period. Treatment of asymptomatic HIV infectious period based on etiology, pathogenesis and syndrome differentiation provided a theoretical foundation for the early intervention of Fuzheng Paidu Tablet to the patients during asymptomatic HIV infectious period.
2 Research on the efficacy of Fuzheng Paidu Tablet to the patients in asymptomatic HIV infectious period indicated that there was statistical significance in the total score after treatment of the two groups at the significance level a=0.05. Effective rate and efficiently individual quantity were higher than that of the control group. There was no statistical significance in the change of CD4+ cell count of the two groups after the treatment. But to calculate the effectiveness by CD4+ cell count increase or decrease by 50/mm3, there is statistical significance between the data before treatment and 6 and 12 months after treatment. However, there was no statistical significance between the data before treatment and 3 and 9 months after treatment, but the efficacy of the treatment group was significantly higher than control group.34 patients in asymptomatic HIV infectious period were randomly selected (1/3 cases of the total number, including 20 patients of the treatment group and 14 patients of the control group) to measure viral load. Compared with the data before treatment, there was no statistical significance in viral load in 6 and 12 months after treatment of the two groups at the significance level a=0.05 (P>0.05), but the efficacy of the treatment was higher than the control group; there was no statistical significance on the change of viral load at the significance level a=0.05 (P>0.05),but the average of the viral load of the treatment group was markedly decreased. Analysis of the quality of life showed that there was statistical significance in the score of energy-latitude, emotional-latitude, pain-latitude, sleep-latitude (P<0.05), there was no statistical significance in the score of physical activity latitude and social life latitude (P> 0.05), but the score of the treatment group was obvious decreased than the score obtained before treatment and lower than the control group. Analysis of the safety indicator of Fuzheng Paidu Tablet found no damage to liver and kidney function, and no adverse effects to routine analysis of blood, urine and stool, and no adverse effects to electrocardiogram and chest X-ray fluoroscopy.
3 The mechanism based on the immune activation related factors of the intervention to the immune regulation of Fuzheng Paidu Tablet showed that after 6 months of treatment, there was statistical significance on the change of IL-6, IL-8, TNF-a, NPI, and IFN-a at the significance level a=0.05(P<0.05), but no statistical significance in sIL-2R (P>0.05). Before treatment there was statistical significance in IL-8, sIL-2R, TNF-a, NPI, and IFN-a compared with the healthy control group (P<0.05), and before treatment, there was no statistical significance in IL-6 compared the healthy control group (P>0.05). Positive correlation exists between each indicator except TNF-αand IFN-α. There was negative correlation between NPI (before treatment) and TNF-α(after treatment), and also negative correlation between fellowing indicators:NPI (after treatment) and TNF-α(after treatment), IFN-α(before treatment) and IL-8 (before treatment), IFN-α(before treatment) and IL-8(after treatment), CD4+ (before treatment) and sIL-2R (before treatment). There was positive correlation between viral load (before treatment) and sIL-2R (before treatment), and also positive correlation between fellowing indicators:viral load (before treatment) and NPI (after treatment), viral load (after treatment) and NPI(before treatment), viral load (after treatment) and NPI (after treatment).
Conclusion:
1 Chinese medicine treatment for HIV/AIDS should take asymptomatic HIV infectious period as the starting point.
2 Fuzheng Paidu Tablet can significantly improve the symptoms and signs of the patients during the asymptomatic HIV infection period, since this has a tendency to increase or stabilize the quantity of CD4 cell, and in some patients it can decrease the viral load, improve the quality of life from different levels and different aspects, and is safe in clinical use.
3 This research suggests that there were close correlation between IL-8, sIL-2R, TNF-a, NPI, IFN-a and the symptom of the asymptomatic HIV infectious period. And cellular immunity correlated to those factors plays an important role in the whole process of the disease, and those factors can be important indicators of the cellular immunity condition and therapeutic effect and prognosis.
4 There were correlations between each indicator, but the mechanism is unknown, and further research is needed on the mechanism of Fuzheng Paidu Tablet in the treatment of the patients during the asymptomatic HIV infection period.
5 This resarch suggest that IL-6, IL-8, TNF-a, NPI, IFN-a have certain significance in determining the efficacy of Fuzheng Paidu Tablet in the treatment of the patients during the asymptomatic HIV infection period. And those factors can serve as important reference indexes.
引文
[1]国家技术监督局.中华人民共和国国家标准HIV/AIDS诊断标准及处理原则(GB 16000-1995)[S].1995：415-416.
[2]王丹妮,彭勃,郭会军,李华伟.艾滋病无症状HIV感染期称谓的探讨与建议[J].中华中医药杂志,2010,25(4)：520-523.
[3]国家中医药管理局.中医药治疗艾滋病临床技术方案(试行)[S].2005：2
[4]彭勃,王丹妮.中医药治疗无症状HIV感染期探析[J].山东中医杂志,2006.25(7)：446-447.
[5]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的关键切入点[J].浙江中医杂志,2006,41(10)：571-572.
[6]郭会军,王丹妮,刘学伟.中医药治疗艾滋病应重视对无症状HIV感染期的早期干预[J].上海中医药杂志,2006,40(7)：17-18.
[7]郭会军,刘学伟,王丹妮.爱康Ⅰ治疗艾滋病相关综合征疗效观察[J].河南中医学院学报,2005,20(6)：6-7.
[8]郭会军,刘学伟,王丹妮.扶正排毒Ⅰ号方治疗无症状HIV感染疗效观察[J].上海中医药杂志,2006,40(1)：20-21.
[9]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的黄金切入点[J].中国临床康复,2006,10(19)：166-167.
[10]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[11]彭勃.研究艾滋病要念好三字经[N].中国中医药报.2005-12-16.
[12]彭勃,李华伟.中医药治疗获得性免疫缺陷综合征的思路和切入点[J].中医杂志.2006；47(6)：412-413.
[13]彭勃,王丹妮.对艾滋病无症状HIV感染期的认识[J].中华中医药杂志,2006,21(11)：663-665.
[14]彭勃,王丹妮.无症状HIV感染期持续时间研究[J].中华中医药学会防治艾滋病学术研讨会暨2006年年会论文集[C]广州：2006,12：1-4.
[15]郭会军,王丹妮.论中医药治疗艾滋病的研究方向[J].中国医药指南,2007,9(9)：116-118
[16]郭会军,王丹妮.探析无症状HIV感染期持续时间[J].中国中医基础医学杂志,2007,13(1)：62-63.
[17]吕维柏,唐家骏,黄尧洲.新世纪康保治疗43例艾滋病人的临床报告[J].中国艾滋病性病防治.2000,6(6)：168-169.
[18]罗士德,来国防,曹建新等.中医药治疗艾滋病的特色[J].中国中西医结合杂志,2002,10(22)：727.
[19]杨凤珍,王健,刘颖等.72例HIV/AIDS患者中医证侯与T淋巴细胞亚群和病毒载量相关性研究[J].中国中医药学报,2004,9(22)：372-375.
[20]林鹏.艾滋病临床学[J].华南预防医学杂志,2004,30(2)：64-68.
[21]卫生部.艾滋病诊疗指南[S].2005：18.
[22]王健.拒绝艾滋[M].第1版.北京：华文出版社.2005.23.
[23]桂希恩.我所知道的艾滋病[M].第1版.武汉：湖北科学技术出版社2003.36.
[24]吕维柏.中医治疗AIDS研究探讨[C].第一届全国中西医结合防治艾滋病学术研讨会论文汇编.北京：2003,4：59.
[25]李思翘泽.AIDS的潜伏时间是否在改变.摘泽自STATISTICS IN MEDICINE
[26]曾毅.警惕艾滋病[M].第1版.北京：清华大学出版社2005.65.
[27]张可.金黄胶囊(金黄口服液)治疗/10例分析[C].第一届全国中西医结合防治艾滋病学术研讨会论文汇编.北京：2003,4：59.
[28]何建凡,冯铁建,李良成,等.HIV感染者的免疫学功能变化及其与病程发展的关系[J].中国性病艾滋病防治,2001,7(1)：1-4.
[29]国外应用中医学防治爱滋病的研究[J],江苏中医药,1986(11)：45.
[30]Naomi Rabinowitz.Acupuncture and AIDS Epidemic:Reflection on the treatment of 200 patients in Four Years[J]. American Journal of Acupuncture.1987,15(1):35.
[31]侯召棠.中医药学防治艾滋病的可行性及试行方案[J].北京中医杂志,1988(1)：49-52.
[32]薛伯寿.从中医理论谈对艾滋病的认识[J].中医杂志,1991(1)：20-22.
[33]张夏.艾滋病的中医辨证研究[J].中医药学报,1991(2)：41.
[34]傅立宁.中医药治疗艾滋病病毒感染者6年观察报告[J].浙江中医杂志,1994(9)：405.
[35]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察[J].国外医学中医中药分册,1996,18(1)：9-11.
[36]周文学,孙阳,伍治平.针灸缓解36例艾滋病病毒感染者症状体会[J].中医杂志,1997,38(10)：602-603.
[37]刘继明.针刺与耳针治疗24例艾滋病患者临床观察[J].针灸临床杂志,1999,15(1)：24-25.
[38]康来仪,潘孝彰,潘启超,等.中药自拟方对18例HIV感染者近期疗效的初步观察[J].中华传染病杂志,1999,17(1)：44-46.
[39]吕维柏,唐家骏,黄尧洲,等.新世纪康保治疗43例艾滋病病人的临床报告[J].中国性病艾滋病防治,2000,6(3)：168-169.
[40]王健,吕维柏,李国勤,等.金生宝胶囊治疗22例HIV感染者的临床研究[J].中国中医基础医学杂志,2000,6(7)：33-35.
[41]王健,于智敏,李国勤,等.中研2号治疗艾滋病感染及艾滋病患者29例临床观察[J].中医杂志,2001,42(7)：418-421.
[42]黄世敬,危剑安,曹惠云,等.中医辨证治疗艾滋病729例临床观察[J].中医杂志,2004,45(9)：680-683.
[43]杨凤珍,烟建华,王健,等HIV/AIDS中医分期辨证治疗[J].中国医药学报,2004,19(4)：240-242.
[44]张可,王健,蒋岩,等.中药治疗200例HIV感染者/AIDS患者的结果分析[J].中国艾滋病性病,2005,11(2)：94-96.
[45]彭勃,王丹妮.扶正排毒片Ⅱ号治疗无症状HIV感染65例临床观察[J].中医药学刊,2006,24(10)：1781-1782.
[46]Peng Bo,Liu Xue-wei,Guo Hui-jun.Effect of fuzheng paidu pian on the changes of CD4+T Lymphocytes in early infective phase of asymptomatic human immunodeficiency virus[J].Journal of Clinical Rehabilitative Tissue Engineering Research August 19,2007 Vol.No.33:6712-6716.
[47]郭会军,郭玉明,刘学伟.中医药对32例无症状HIV感染者早期干预的临床观察[C].中华中医药学会防治艾滋病学术研讨会暨2007年年会,2007,11,224-226.
[48]彭勃,郭会军,刘学伟.中医不同治法对166例无症状人类免疫缺陷病毒感染者CD4+T淋巴细胞的影响[J].中医杂志,2008,49(2)：142-143.
[49]郭会军,陈继忠,郭玉明.扶正排毒颗粒对32例艾滋病无症状者早期干预观察[J].中国中医药现代远程教育,2008,6(6)：528-529.
[50]王丹妮,郭会军,李华伟,等.扶正排毒片Ⅱ号治疗无症状HIV感染65例疗效观察[J].中华中医药杂志,2009,24(3)：385-388.
[51]李华伟.论艾滋病慢性进展期中医药治疗[J].中医学报,2010,(4)：6-7.
[52]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南[J].中华传染病志,2005,24(2)：133-144.
[53]李太生,王爱霞,邱志峰.艾滋病的免疫发病机制和免疫重建[J].中华医学杂志,2001,81(5)：310-313.
[54]Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy[J]. Nat Med.1999,5(5):512-7.
[55]Sedaghat AR, Siliciano RF, Wilke CO.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART[J].BMC Infect Dis.2008,(2):2.
[56]罗玲,李太生HIV/AIDS研究承载新知继续前行[N]..中国医学论坛报,2009-1-15,A9-A10.
[57]Donald L.Sodora,Guido Silvestri.Immune activation and AIDS pathogenesis[J]. AIDS,2008, (22):439-446.
[58]BRAUNWALD FAUCI,KASPER HAUSER,LONGO JAMESON王德炳主译.哈里森内科学(第十五版)[M].,北京：人民卫生出版社,2003,2280,2293.
[59]Fransje A. Koning, Sigrid A. Otto, Mette D. Hazenberg,et al. Low-Level CD4 Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection[J].The Journal of Immunology.2005,(175): 6117-6122.
[60]Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency[J].J Acquir Immune Defic Syndr Hum Retrovirol.1998,18(4):332-40.
[61]Mette D. Hazenberg; Sigrid A. Otto; Birgit H. B. van Benthem; Marijke Th. L. Roos; Roel A. Coutinho; Joep M. A. Lange; Dorte Hamann; Maria Prins; Frank Miedema.Persistent immune activation in HIV-1 infection is associated with progression to AIDS[J].AIDS.2003,17(13):1881-1888.
[62]Vajpayee M, Kaushik S, Sreenivas V, Mojumdar K, Mendiratta S, Chauhan NK. Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients[J]. Eur J Clin Microbiol Infect Dis. 2009,28(1):69-73.
[63]John J. Zaunders, Mee Ling Munier, Daniel E. Kaufmann, Susanna Ip, Pat Grey,et al. Early proliferation of CCR5 CD38 antigen-specific CD4_ Thl effector cells during primary HIV-1 infection.Blood. 2005,106:1660-1667
[64]ThomasW. McCloskey, Saroj Bakshi, Soe Than, et al.Immuno phenotypic Analysis of Peripheral Blooc Mononuclear Cells Undergoing In Vitro Apoptosis After Isolation From Human Immunodeficiency Virus-Infected Children[J].Blood.1998,92(11):4230-4237.
[65]Soe Than,Monica Kharbanda,Vivek Chitnis,et al.Clonal Dominance Patterns of CD8 T Cells in Relation to Disease Progression in HIV-Infected Children[J].The Journal of Immunology.1999,162:3680-3686.
[66]Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions[J].Nat Immunol.2003,(4):49-54.
[67]Ascher MS, Sheppard HW. AIDS as immune system activation:a model for pathogenesis. Clin Exp Immunol.1988,73:165-167.
[68]Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB,et al. Immune activation set point during early HIV infection predicts subsequent CD4R T-cell changes independent of viral load[J]. Blood. 2004,104:942-947.
[69]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究[J].中国实用内科杂志,2007,27(11)：847-850.
[70]Shailesh K. Choudhary,Nienke Vrisekoop,Christine A. Jansen,et al.Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease[J]. JOURNAL OF VIROLOGY.2007,(8):8838-8842.
[71]ZHANG Zi-ning, SHANG Hong, JIANG Yong-jun, LIU Jing, DAI Di, DIAO Ying-ying, GENG Wen-qing, JIN Xin and WANG Ya-nan.Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients[J]. Chin Med J.2006; 119(23):1966-1971.
[72]Steven G. Deeks, Christina M. R. Kitchen, Lea Liu, et al.Immune activation set point during early HIV infection predicts subsequent CD4Tcell changes independent of viral load[J]. Blood.2004,104:942-947.
[73]Ana E. Sousa, Jorge Carneiro, Martin Meier-Schellersheim, et al.CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load[J]. The Journal of Immunology.2002,169:3400-3406.
[74]Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, Moroni M, Clerici M, Gori A.Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics[J]. AIDS. 2004,18(2):211-216.
[75]Por Manuel Crespo, Isabel Caragol, Vicenc Falco, Esteban Ribera, Susana Urban, Albert Pahissa. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART[J].Enferm Infecc Microbiol Clin.2008,26:27-31.
[76]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察[J].国外医学中医中药分册.1996,18(1)：9-11.
[77]黄世敬,危剑安.中医治疗十年以上21例艾滋病病例报告[J].中国医药学报,2004,19(12)：731-732.
[78]吴维萍,朱琳,聂勇,郭长河.灭艾灵汤剂治疗早中期艾滋病70例[J].中医研究,2004,17(6)：30.
[79]王融冰,王晓静,王玉光.健脾益气法治疗艾滋病38例临床观察[J].北京中医.2007,26(1)：9-11.
[80]谢世平,潘万旗,郭会军,等。爱康胶囊对HIV/AIDS患者免疫功能影响的研究[J].辽宁中医杂志.2008,35(2)：165-167.
[81]河南省中医药治疗艾滋病临床专家组.益艾康胶囊对379例无症状期感染者的干预[J].中医研究.2008,21(3)：31-33.
[82]赵红心,张福杰.中西医结合治疗艾滋病的机遇与挑战[J].中国艾滋病性病.2008,14(4)：425-428.
[83]MosmannTR, CherwinskiH, Bond MW, etal.Two type of murinehelPer T cell clones.Definition according to Profiles of lymPhokine ac-tivities and secreted Proteins[J].J Immunol,1986,136:2348-2363.
[84]白雪帆,张树林.艾滋病的诊断与治疗[M].北京：人民军医出版社,2000：99-101.
[85]曹岩,刘红,卢晟晔,等。儿童肺炎支原体肺炎血清中TNF-a、IL-6、IL-8和IL-10浓度测定及其临床意义的研究[J],中国妇幼保健杂志2008,23(18)2575-2577
[86]Gfiffths CEM,Voor hees JJ,Nickoloff BJ. Characterization of intercellar adhesion molecular-1 and HLA-DR expression in normal and inflamed skin:modulation by recombinant interferon and tum-or necrosis factor [J]. Am Acad Deratol,1989,20:617-622.
[87]王胜奇,李春盛.新蝶呤在感染性疾病诊断中的作用[J].感染.炎症.修复.2008：12-20
[88]吴伯平,陆寿康.中医中药治疗爱滋病的探索性意见[J].北京中医杂志,1986,1：14-16.
[89]薛伯寿.从中医理论谈对艾滋病的认识[J].中医杂志,1991,32(1)：20-22.
[90]尤松鑫.艾滋病中医证治概述[J].江苏中医,1999,20(3)：3-5.
[91]孙利民,危剑安,黄霞珍,等.从中医理论谈艾滋病的发病机制[J].中华中医药杂志,2005,20(2)：100-101.
[92]孟澍江.温病学[M].上海科学技术出版社,1985.6-14.
[93]徐莲芝.实用艾滋病防治指南[M].天津科学技术出版社,2001,1：459.
[94]楼孝惠,陈智,黄茵,等.慢性乙型肝炎中医证型IL-2、IL-10、IL-12、IFN-γ水平的关系初探[J].中西医结合肝病杂志,2001,11(5)：282-283.
[95]周小军,孙克伟.慢性乙型病毒性肝炎患者Th1、Th2细胞因子与中医证型之关系[J].湖北中医杂志,2005,27(1)：17-18.
[96]王芹.扶正抗艾方”对HIV/AIDS患者IL-2及IFN-γ影响的研究[D].湖北中医学院硕士论文,2009-05-10.
[97]邓家驹.论中医免疫医学思想及其物质基础[J].中国中医基础医学杂志,1999,5(11)：22-23.
[98]侯安继,刘源.中医药治疗艾滋病研究进展[J].北京中医药大学学报,2003,10(1)：60-62.
[99]Watanabe K.传统汉方方剂对艾滋病病毒感染的病人外周单核类细胞在体外的免疫调节作用[J].国外医学：中医中药分册,1991,13(3)：14-18.
[100]张志军.小柴胡汤提取剂对感染细胞吞噬作用[J].国外医学：中医中药分册,1995,17(1)：64.
[101]王健,许建阳.中医药治疗艾滋病的现状及前景[J].武警医学,2003,4(10)：285-288.
[102]李延斌.六味地黄丸的新功效[J].江苏卫生保健,2004,(4)：21.
[103]李国勤.中医药治疗艾滋病呼吸道感染的临床观察[J].中医杂志,1993,(12)：671.
[104]张永祥,刘颖,王健.154例HIV/AIDS患者T细胞亚群检测结果分析[J].中国艾滋病性病,2004,10(6)： 463-464.
[105]刘静,张旻,张子宁.艾滋病病毒感染者淋巴细胞总数和CD4阳性T淋巴细胞数相关性的研究[J].中华检验医学杂志,2004,27(3)：156-158.
[106]李莉,魏飞力.HIV1感染者体内自然杀伤T细胞和免疫抑制性T细胞的变化[J].中国抗感染化疗杂志2003,3(6)：328-331.
[107]周华英HAART和H IV感染的免疫重建[J].国外医学免疫学分册,2005,28(5)：270-274.
[108]秦卫兵.TH1和TH2细胞在体内的分化[J].国外医学,免疫学分册,2002,25(1)：42-44.
[109]JayA. Levy,杨月.HIV的致病机理与细胞因子相关的病毒学及免疫学特性(下)[J].传染病网络动态,2004,12,31-32.
[110]张兴权,范江主编.艾滋病毒感染与艾滋病[M].第一版.北京：人民卫生出版社,2001：124
[111]张旻,尚红,张远志.新疆、辽宁地区HIV1感染者细胞因子特征研究[J].中国免疫学杂志,2003,19(6)：418-420.
[112]彭勃,苗明三,郭会军,等.扶正排毒片干预环磷酰氨致免疫抑制小鼠免疫功能的效应[J].中国临床康复,2006：10(43)：126-128.
[113]彭勃,苗明三,郭会军,等.扶正排毒片对轻化可的松致免疫抑制小鼠免疫功能的调节[J].中国临床康复,2006：10(39)：141-143.
[114]李伟,彭勃,刘景超,等.扶正排毒片水提取物抑制HIV-1病毒活性的实验研究[J].河南中医学院学报,2007,22(5)：1-5.
[115]张娴,力曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20-22.
[116]吕圭源,李万里,刘明哲.白术抗衰老作用研究[J].中国现代应用药学,1996,13(5)：26-29.
[117]张萍,祝希娴.甘草及其制剂药理与临床应用研究新进展[J].中草药,1997,28(9)：568.
[118]李铁民,梁再赋.甘草提取物及其衍生物的抗病毒研究现状[J].中草药,1994,25(12)：655.
[119]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究[J].中国实用内科杂志,2007,27(11)：847-850.
[120]苏立稳.试论获得性免疫缺陷综合征得中医病机[J].陕西中医,1994,15(4)：164.
[121]鲍作义,李林,庄道民,等.HIV感染者CD4/CD8细胞与病毒载量的关系[J].中国公共卫生,2003,19(11)：1380-1381.
[122]姚均,何忠平,张建平.应用流式细胞仪研究HIVAIDS患者的免疫状况[J].临床输血与检验,2002,4(1)：9-11.
[123]袁伟杰,郭峰.细胞因子与肾小球肾炎[J].上海免疫学杂志,1992,12(2)：191-192.
[124]漆以芹.消化性溃疡病患者治疗前后血清GM-CSF、IL-8和IL-6水平检测的临床意义[J].中国临床实用医学,2009,3(12)93-94.
[125]曹岩,刘红,卢晟晔,等.儿童肺炎支原体肺炎血清中TNF-a、IL-6、IL-8和IL-10浓度测定及其临床意义的研究[J].中国妇幼保健杂志,2008,23(18)：2575-2577.
[126]黄雪涛.细胞因子与疾病的治疗[J].中国免疫学杂志,1994,2：129.
[127]Kim JM,Oh YK.Kim YJ, et al.Polarized secretion of CXC chemokines by human intestinal epithelial cells in response to Bacteroides fragilis enterotoxin:NF-kappa B plays a major role in the regulation of IL-8 expression[J].Clin Exp lmmunol,2001,123(3):421-427.
[128]Nanthakumar NN, Fusunyan RD, Sanderson I, et al. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis[J].Proc Natl Acad SciUSA.2000,97(11): 6043-6048.
[129]陈克敏.细胞因子与肾炎[J].国外医学免疫学分册,1992,1(2)：75-76.
[130]董林,李明,张元英.肺炎支原体肺炎患儿细胞因子测定的探讨[J].放射免疫学杂志,2002,15(1)：1-2.
[131]闫柏刚.严重刨伤后新蝶呤/生物蝶呤的变化及意义[J].国外医学·临床生物化学与检验学分册.1999,20(3)：122-123.
[132]岑玉文HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究[D].广州中医药大学博士论文,2008-04-01
[133]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1)：8-17.
[134]Chung KF.C ytokines in chronic obstructive pulmonary disease[J].EurRespir,2001,18:50-59.
[135]王胜,徐风珍,陈余清.慢性阻塞性肺疾病痰液白细胞介素8、6和肿瘤坏死因子测定及其意义[J].中华结核和呼吸杂志,2000,23：465467.
[1]尤松鑫.艾滋病中医证治概述[J].江苏中医,1997,20(3)：3-5.
[2]黄炳山.中医治疗艾滋病[M].哈尔滨：黑龙江科学技术出版社,1990,25.
[3]彭勃,刘爱华,谢世平.艾滋病中医病病机及发病途径之思考[C].中华中医药学会防治艾滋病学术研讨会暨2006年年会,2006年12月,26.
[4]苏诚炼.中医药试治艾滋病30例临床报告[J].中医杂志,1990,31(3)：27.
[5]蒋心悦.浅谈艾滋病的病因病机[J].中国医药学报,2001,16(6).
[6]陈瑀.卫气浅谈——艾滋病辨病探索[J].中国中医基础医学杂志,2002,8(4)：11.
[7]侯安继,刘源.中医药治疗艾滋病研究进展[J].北京中医药大学学报,2003,10(1)：60-62.
[8]向楠,李晓东.中医药治疗艾滋病研究进展[J].湖北中医学院学报,2004,6(4)：92-93.
[9]杨凤珍,烟建华,王健.艾滋病元气损伤病机的研究[J].中国中医基础医学杂志,2005,11(2)：147-148下转138.
[10]黄碧群,朱镇华证素概念的辨析[J].中华中医药杂志,2005,20(5)：273-274.
[11]溥敏敏中医“证素”研究[J].时珍国医国药,2008,19(6)：1490-1450.
[12]马斌,高颖.中风病恢复期证候要素的研究[J].江苏中医药,2007,39(1)：27.
[13]马斌,高颖.中风病发病第7天和第14天证候要素演变规律初步研究[J].辽宁中医杂志.2006,33(12)：1561.
[14]张启明,王永炎,张志斌,等.外感病因中证候要素的提取[J].山东中医药大学学报,2005,29(5)：339.
[15]彭勃,谢世平,苏春娅,等.艾滋病中医辨证方法探析[C],2004年中华中医药学会年会论文集,28.
[16]方路,王莉,段呈玉,等.云南省180例HIV/AIDS的中医症状及证候的初步分析[J].云南中医中药杂志,2006,27(3)：40-41.
[17]谢世平,潘万旗,梁慕华.艾滋病中医基本证型的相关文献分析[J].河南中医学院学报,2006,21(122)：6-8.
[18]杨凤珍,烟建华,王健,等HIV/AIDS中医分期辨证治疗[J].中国医药学报.2004,19(4)：240-242..
[19]5省中医药治疗艾滋病项目临床技术培训资料.国家中管局.2004,8.
[20]黄世敬,危剑安.中医治疗十年以上21例艾滋病病例报告[J].中国医药学报,2004,19(12)：731-732.
[21]李国勤.艾滋病中医辨治体会[J].江苏中医.1994,15(2).
[22]王宝祥,石昌德,董雪梅.中医药抗艾滋病的临床研究[J].空军医高专报.1998,20(1)
[23]崔述贵等.艾滋病的辨证论治探微.中医函授通讯.1994,13(5)：32-35
[24]秦国政,李庆生,张春和,等.艾滋病中医发病学特点及中医证候数据库建立研究简报[J].云南中医学院学报,2008,31(2)：43-45
[25]杨凤珍,王健,赵敏,等.72例HIV/AIDS患者中医证候与T淋巴细胞亚群和病毒载量相关性研究[J].中国医药学报,2004,19(12)：733-737.
[26]黎耘,周正质.中医药防治艾滋病的研究现状与前景展望[J].天然产物研究与开发,2003,15(3)：273-276.
[27]王朝霞,宋丽君.甘草甜素的研究现状[J].中国中西医结合杂志,2002,22(10)：796-798.
[28]王家骅,王晓光.中药抗癌抗艾滋病作用[J].时珍国医国药,2000,11(3)：276-277.
[29]严启新,罗天浩.苦瓜的研究与开发思考[J].时珍国药研究,1997,8(4)：380-380.
[30]李庆宪,侯安继.中药治疗艾滋病的研究进展[J].时珍国医国药,2003,14(7)421-423.
[31]赵晶,张致平,陈鸿珊,等.黄芩甙元及其苄基衍生物的制备与抗人免疫缺陷病毒实验研究[J].药学学报1997,32(2)：140-143.
[32]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(11)：20-22.
[33]蔡德,佘白蓉,杨绮华.淫羊藿总黄酮提取及其含量测定[J].广东药学院学报,2005,21(1)：75-76.
[34]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000.7(1)20-22.
[35]张志军.艾滋病与汉方[J].国外医学中医中药分册,1995,17(3)：11-13.
[36]吴维萍,朱琳,聂勇.灭艾灵汤剂治疗早中期艾滋病70例[J].中医研究,2004,17(6)：30
[37]张永祥,温瑞兴,关崇芬.中研Ⅰ号、中研Ⅱ号和艾通冲剂对HIV/AIDS患者病毒载量与免疫功能作用的观察[J].中国中医基础医学杂志,2004,10(8)：41-42.
[38]徐淑玲,吴小娴.扶正祛邪中药复方对猴艾滋病模型实验研究[J].中国实验方剂学杂志,2003,9(1)：42-44.
[39]张其威,张楚瑜.抗病毒中药研究的最新进展[J].中成药,2005,27(1)：116-119.
[40]作者无.我国抗艾滋病中药在泰国上市[J].中医药国际参考,2008,1：24-25.
[41]张永容,苏斌练.抗艾滋病药物“中药2号”复方的初步研究[J].医学研究通讯,1998,27(11)：37-39.
[42]关崇芬,王健,徐淑玲.中研2号治疗HIV/AIDS的临床和实验研究[J].中国中西医结合杂志,2003,23(7)：494-497.
[43]韩桂华.中医药治疗艾滋病60例临床观察[J].中医杂志2004,45(7)：515-516.
[44]孟坤.喘可治一种多功能的免疫调节剂在艾滋病上的临床应用研究[A].2004年年会及防治艾滋病培训会议资料[C].郑州：2004,31.
[45]兰金初,李德益.三归片治疗艾滋病临床研究[J].河南中医学院学报,2005,20(1)：11-12
[46]吕维柏.新世纪康保治疗43例艾滋病人的临床报告[J].中国中西医结合杂志,2003,23(7)：494-497.
[47]吕维柏.金龙胶囊治疗感染者20例初步报告[J].中国艾滋病性病,2004,10(1)：18-19.
[48]吴昊.唐草片治疗HIV/AIDS的临床研究[A].中医药治疗艾滋病的研究进展[C].北京：中医古籍出版社,2004,4：103.
[49]张可.金黄胶囊(金黄口服液)治疗/10例分析[A].第一届全国中西医结合防治艾滋病学术研讨会论文汇编[C].北京：2003,4：59.
[50]田圣志.爱可扶正片治疗艾滋病99例临床疗效分析[A].中国艾滋病药物治疗研讨会资料汇编[C],2001,9：160-166.
[51]王丹妮.非药物疗法在艾滋病治疗中的运用[A].中华中医药学会防治艾滋病国际学术研讨会论文集[C],郑州：2007-11-24.
[52]王丹妮.非药物疗法在艾滋病治疗中的运用[J].中国医药指南,2007,9：118-120.
[53]舒钟民.实用非药物疗法大全[M].北京：中国古籍出版社,1999：3.
[54]蔡德英.浅析非药物疗法与针灸治疗[J].中国中医药信息杂志,2005.(12)12：5-6.
[55]尹勇,段丽萍,刘玉生.针灸治疗艾滋病23例[J].上海中医药大学学报,2002,16(2)：29-30.
[56]刘继明.针刺与耳针治疗24例艾滋病患者临床观察[J].针灸临床杂志,1999(15)1：24-25.
[57]王健.艾滋病的中医辨证论治初探[J].贵阳中医学院学报,1995,(4)：1.
[58]M.D. Smith. abstract.Presented at World Conress of Acupun and Natural Med.Beijing 1987:11.
[59]墨西哥AIDS治疗中心.中医药治疗艾滋病效果好[J].中医药动态,1989,(7)：51.
[60]M.Goh et al.Amer J.Acupun.1992;(4):361.
[61]韦玲.针刺治疗艾滋病并发周围神经病变的临床观察[J].中国针灸,2003,23(1)：9-10.
[62]吴欣.针灸治疗艾滋病并发带状疱疹43例[J].江苏中医,2002,10：431.
[63]杨甲三,曹一鸣.腧穴学[M].上海：上海科学技术出版社,1984：189-190.
[64]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[65]李崇忠,李静.中医药治疗艾滋病理论的建立与临证应用[J].实用中医内科杂志,2002,16(2)：62-65.
[66]赵丹,李峰,张宁.中医非药物疗法防治艾滋病研究进展[J].北京中医药大学学报,2006,29(1)：63-66.
[67]王磊.艾灸疗法作用机理国内外研究进展[J].中国针灸,2001,21(9)：567-570.
[68]江苏新医学院.中药大辞典·上册[M]上海：上海科学技术出版社,1986：560.
[69]王融冰.中医药治疗艾滋病的研究概况[J].继续医学教育,2006,20(19)：67-73.
[70]方旭.艾滋病的中医饮食疗法[J].东方食疗与保健,2006,1(23).
[71]俞福康译.双足与保健[J].2003年第2期.
[72]王明辉.重视艾滋病的中医药治疗[J].专家讲坛,2003,2(10).
[73]张妍玲.双黄连粉针剂治疗艾滋病的临床观察[J].山西医科大学学报,1999,30(2)：177-179.
[74]彭勃,王丹妮.对艾滋病无症状HIV感染期的认识[J].中华中医药杂志,2006,21(11)：663-665.
[75]郭会军,王丹妮.探析无症状HIV感染期持续时间[J].中国中医基础医学杂志,2007,13(1)：62-63.
[76]王丹妮,彭勃,郭会军,李华伟.艾滋病无症状HIV感染期称谓的探讨与建议[J].中华中医药杂志,2010,25(4)：520-523.
[77]彭勃,王丹妮.中医药治疗无症状HIV感染期探析[J].山东中医杂志,2006.25(7)：446-447.
[78]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的关键切入点[J].浙江中医杂志,2006,41(10)：571-572.
[79]郭会军,王丹妮,刘学伟.中医药治疗艾滋病应重视对无症状HIV感染期的早期干预[J].上海中医药杂志,2006,40(7)：17-18.
[80]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的黄金切入点[J].中国临床康复,2006,10(19)：166-167.
[81]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[82]彭勃.研究艾滋病要念好三字经[J].中国中医药报.2005年12月16日
[83]彭勃,李华伟.中医药治疗获得性免疫缺陷综合征的思路和切入点[J].中医杂志.2006；47(6)：412-413.
[84]彭勃,王丹妮.无症状HIV感染期持续时间研究.中华中医药学会防治艾滋病学术研讨会暨2006年年会论文集[C]广州：2006,12：1-4.
[85]郭会军,王丹妮.论中医药治疗艾滋病的研究方向.中国医药指南,2007,9(9)：116-118
[86]王丹妮,彭勃,郭会军.中医药治疗艾滋病疗效评价探析[J].中国中医基础医学杂志,2010,16(12)：1102-1103.
[87]Levin J S, Glass T A. Kushi L H, et al. Quantitative methods in research on complementary and alternative medicine. A methodological manifesto [S]. Med Care,1997,35(11):1079.
[88]吕维柏,王健,关崇芬.中医药治疗艾滋病的研究进展[M].北京：中国古籍出版社,2004,87-95.
[89]郭会军,刘学伟,王丹妮.扶正排毒片对艾滋病无症状期的疗效观察[J].上海中医药杂志,2006,40(1)：20-21.
[90]郭会军,刘学伟,王丹妮.爱康Ⅱ治疗艾滋病相关综合征疗效观察[J].河南中医学院学报,2005,20(6)：6-7.
[91]高洪才,李幼平,张伯礼.中医药临床疗效评价实践中的几点思考[J].天津中医药,2007,24(4)：275-276.
[92]王健,刘颖.关于中医药治疗艾滋病疗效评价的认识与思考[J].河南中医学院学报,2006,21(6)：6-8.
[93]鞠鹏,罗士德.对中药治疗艾滋病疗效评价体系的儿点看法[J].河南中医学院学报,2007,22(2)：1-2.
[94]张健,王沛.生存质量和中医整体观在肿瘤疗效评价中的意义[J].中医药管理杂志,2007,15(1)：56-58.
[95]刘建平.循证中医药临床研究方法学[M].北京：人民卫生出版社,2006,前言.
[96]梁润英,谢世平,闫国立.中医药治疗艾滋病临床文献质量评价[J].中医研究,2008,21(3)：34-36.
[97]曾毅.警惕艾滋病[M].第1版.清华大学出版社北京：2005.65.
[98]何建凡,冯铁建,李良成,等.HIV感染者的免疫学功能变化及其与病程发展的关系[J].中国性病艾滋病防治,2001,7(1)：1-4.
[99]王丹妮,郭会军,李华伟.扶正排毒片Ⅱ号治疗无症状HIV感染者65例疗效观察[J].中华中医药杂志,2009,24(3)：385-388.
[100]张伯礼,康立源,项耀祖.中药新药临床试验中有关疗效评价若干问题的思考[J].中药新药与临床杂志,2007,26(11)：861-863.
[101]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南.中华传染病志,2005,24(2)：133-144.
[102]李太生,王爱霞,邱志峰.艾滋病的免疫发病机制和免疫重建.中华医学杂志,2001,81(5)：310-313.
[103]Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med.1999,5(5):512-7.
[104]Sedaghat AR, Siliciano RF, Wilke CO.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.BMC Infect Dis.2008,(2):2.
[105]罗玲,李太生HIV/AIDS研究承载新知继续前行.中国医学论坛报,2009-1-15,A9-A10.[106]Donald L.Sodora,Guido Silvestri.Immune activation and AIDS pathogenesis. AIDS,2008, (22):439-446.
[107]BRAUNWALD FAUCI,KASPER HAUSER,LONGO JAMESON王德炳主译.哈里森内科学(第十五版),北京：人民卫生出版社,2003,2280,2293.
[108]Fransje A. Koning, Sigrid A. Otto, Mette D. Hazenberg,et al. Low-Level CD4 Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection.The Journal of Immunology.2005,(175):6117-6122.
[109]Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol.1998,18(4):332-40.
[110]Mette D. Hazenberg; Sigrid A. Otto; Birgit H. B. van Benthem; Marijke Th. L. Roos; Roel A. Coutinho; Joep M. A. Lange; Dorte Hamann; Maria Prins; Frank Miedema.Persistent immune activation in HIV-1 infection is associated with progression to AIDS.AIDS.2003,17(13):1881-1888.
[111]Vajpayee M, Kaushik S, Sreenivas V, Mojumdar K, Mendiratta S, Chauhan NK. Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients. Eur J Clin Microbiol Infect Dis.2009,28(1):69-73.
[112]John J. Zaunders, Mee Ling Munier, Daniel E. Kaufmann, Susanna Ip, Pat Grey,et al. Early proliferation of CCR5 CD38 antigen-specific CD4_ Thl effector cells during primary HIV-1 infection.Blood. 2005,106:1660-1667
[113]ThomasW. McCloskey, Saroj Bakshi, Soe Than, et al.Immuno phenotypic Analysis of Peripheral Blood Mononuclear Cells Undergoing In Vitro Apoptosis After Isolation From Human Immunodeficiency Virus-Infected Children. Blood. 1998,92(11):4230-4237.
[114]Soe Than,Monica Kharbanda,Vivek Chitnis,et al.Clonal Dominance Patterns of CD8 T Cells in Relation to Disease Progression in HIV-Infected Children. The Journal of Immunology.1999,162:3680-3686.
[115]Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol.2003,(4):49-54.
[116]Ascher MS, Sheppard HW. AIDS as immune system activation:a model for pathogenesis. Clin Exp Immunol.1988,73:165-167.
[117]Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB,et al. Immune activation set point during early HIV infection predicts subsequent CD4R T-cell changes independent of viral load. Blood. 2004,104:942-947.
[118]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究.中国实用内科杂志,2007,27(11)：847-850.
[119]Shailesh K. Choudhary,Nienke Vrisekoop,Christine A. Jansen.et al.Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease. JOURNAL OF VIROLOGY.2007,(8):8838-8842.
[120]ZHANG Zi-ning, SHANG Hong, JIANG Yong-jun, LIU Jing, DAI Di, DIAO Ying-ying, GENG Wen-qing, JIN Xin and WANG Ya-nan.Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients. Chin Med J.2006; 119(23):1966-1971.
[121]Steven G. Deeks, Christina M. R. Kitchen, Lea Liu, et al.Immune activation set point during early HIV infection predicts subsequent CD4Tcell changes independent of viral load. Blood.2004,104:942-947.
[122]Ana E. Sousa, Jorge Carneiro, Martin Meier-Schellersheim, et al.CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load. The Journal of Immunology.2002,169:3400-3406.
[123]Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, Moroni M, Clerici M, Gori A.Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS. 2004,18(2):211-216.
[124]Por Manuel Crespo, Isabel Caragol, Vicenc Falco, Esteban Ribera, Susana Urban, Albert Pahissa. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.Enferm Infecc Microbiol Clin.2008,26:27-31.
[125]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察.国外医学中医中药分册.1996,18(1)：9-11.
[126]吴维萍,朱琳,聂勇,郭长河.灭艾灵汤剂治疗早中期艾滋病70例.中医研究,2004,17(6)：30.[127]王融冰,王晓静,王玉光.健脾益气法治疗艾滋病38例临床观察.北京中医.2007,26(1)：9-11.
[128]谢世平,潘万旗,郭会军,等。爱康胶囊对HIV/AIDS患者免疫功能影响的研究.辽宁中医杂志.2008,35(2)：165-167.
[129]河南省中医药治疗艾滋病临床专家组.益艾康胶囊对379例无症状期感染者的干预.中医研究.2008,21(3)：31-33.
[130]赵红心,张福杰.中西医结合治疗艾滋病的机遇与挑战.中国艾滋病性病.2008,14(4)：425-428.
[2]王丹妮,彭勃,郭会军,李华伟.艾滋病无症状HIV感染期称谓的探讨与建议[J].中华中医药杂志,2010,25(4)：520-523.
[3]国家中医药管理局.中医药治疗艾滋病临床技术方案(试行)[S].2005：2
[4]彭勃,王丹妮.中医药治疗无症状HIV感染期探析[J].山东中医杂志,2006.25(7)：446-447.
[5]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的关键切入点[J].浙江中医杂志,2006,41(10)：571-572.
[6]郭会军,王丹妮,刘学伟.中医药治疗艾滋病应重视对无症状HIV感染期的早期干预[J].上海中医药杂志,2006,40(7)：17-18.
[7]郭会军,刘学伟,王丹妮.爱康Ⅰ治疗艾滋病相关综合征疗效观察[J].河南中医学院学报,2005,20(6)：6-7.
[8]郭会军,刘学伟,王丹妮.扶正排毒Ⅰ号方治疗无症状HIV感染疗效观察[J].上海中医药杂志,2006,40(1)：20-21.
[9]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的黄金切入点[J].中国临床康复,2006,10(19)：166-167.
[10]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[11]彭勃.研究艾滋病要念好三字经[N].中国中医药报.2005-12-16.
[12]彭勃,李华伟.中医药治疗获得性免疫缺陷综合征的思路和切入点[J].中医杂志.2006；47(6)：412-413.
[13]彭勃,王丹妮.对艾滋病无症状HIV感染期的认识[J].中华中医药杂志,2006,21(11)：663-665.
[14]彭勃,王丹妮.无症状HIV感染期持续时间研究[J].中华中医药学会防治艾滋病学术研讨会暨2006年年会论文集[C]广州：2006,12：1-4.
[15]郭会军,王丹妮.论中医药治疗艾滋病的研究方向[J].中国医药指南,2007,9(9)：116-118
[16]郭会军,王丹妮.探析无症状HIV感染期持续时间[J].中国中医基础医学杂志,2007,13(1)：62-63.
[17]吕维柏,唐家骏,黄尧洲.新世纪康保治疗43例艾滋病人的临床报告[J].中国艾滋病性病防治.2000,6(6)：168-169.
[18]罗士德,来国防,曹建新等.中医药治疗艾滋病的特色[J].中国中西医结合杂志,2002,10(22)：727.
[19]杨凤珍,王健,刘颖等.72例HIV/AIDS患者中医证侯与T淋巴细胞亚群和病毒载量相关性研究[J].中国中医药学报,2004,9(22)：372-375.
[20]林鹏.艾滋病临床学[J].华南预防医学杂志,2004,30(2)：64-68.
[21]卫生部.艾滋病诊疗指南[S].2005：18.
[22]王健.拒绝艾滋[M].第1版.北京：华文出版社.2005.23.
[23]桂希恩.我所知道的艾滋病[M].第1版.武汉：湖北科学技术出版社2003.36.
[24]吕维柏.中医治疗AIDS研究探讨[C].第一届全国中西医结合防治艾滋病学术研讨会论文汇编.北京：2003,4：59.
[25]李思翘泽.AIDS的潜伏时间是否在改变.摘泽自STATISTICS IN MEDICINE
[26]曾毅.警惕艾滋病[M].第1版.北京：清华大学出版社2005.65.
[27]张可.金黄胶囊(金黄口服液)治疗/10例分析[C].第一届全国中西医结合防治艾滋病学术研讨会论文汇编.北京：2003,4：59.
[28]何建凡,冯铁建,李良成,等.HIV感染者的免疫学功能变化及其与病程发展的关系[J].中国性病艾滋病防治,2001,7(1)：1-4.
[29]国外应用中医学防治爱滋病的研究[J],江苏中医药,1986(11)：45.
[30]Naomi Rabinowitz.Acupuncture and AIDS Epidemic:Reflection on the treatment of 200 patients in Four Years[J]. American Journal of Acupuncture.1987,15(1):35.
[31]侯召棠.中医药学防治艾滋病的可行性及试行方案[J].北京中医杂志,1988(1)：49-52.
[32]薛伯寿.从中医理论谈对艾滋病的认识[J].中医杂志,1991(1)：20-22.
[33]张夏.艾滋病的中医辨证研究[J].中医药学报,1991(2)：41.
[34]傅立宁.中医药治疗艾滋病病毒感染者6年观察报告[J].浙江中医杂志,1994(9)：405.
[35]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察[J].国外医学中医中药分册,1996,18(1)：9-11.
[36]周文学,孙阳,伍治平.针灸缓解36例艾滋病病毒感染者症状体会[J].中医杂志,1997,38(10)：602-603.
[37]刘继明.针刺与耳针治疗24例艾滋病患者临床观察[J].针灸临床杂志,1999,15(1)：24-25.
[38]康来仪,潘孝彰,潘启超,等.中药自拟方对18例HIV感染者近期疗效的初步观察[J].中华传染病杂志,1999,17(1)：44-46.
[39]吕维柏,唐家骏,黄尧洲,等.新世纪康保治疗43例艾滋病病人的临床报告[J].中国性病艾滋病防治,2000,6(3)：168-169.
[40]王健,吕维柏,李国勤,等.金生宝胶囊治疗22例HIV感染者的临床研究[J].中国中医基础医学杂志,2000,6(7)：33-35.
[41]王健,于智敏,李国勤,等.中研2号治疗艾滋病感染及艾滋病患者29例临床观察[J].中医杂志,2001,42(7)：418-421.
[42]黄世敬,危剑安,曹惠云,等.中医辨证治疗艾滋病729例临床观察[J].中医杂志,2004,45(9)：680-683.
[43]杨凤珍,烟建华,王健,等HIV/AIDS中医分期辨证治疗[J].中国医药学报,2004,19(4)：240-242.
[44]张可,王健,蒋岩,等.中药治疗200例HIV感染者/AIDS患者的结果分析[J].中国艾滋病性病,2005,11(2)：94-96.
[45]彭勃,王丹妮.扶正排毒片Ⅱ号治疗无症状HIV感染65例临床观察[J].中医药学刊,2006,24(10)：1781-1782.
[46]Peng Bo,Liu Xue-wei,Guo Hui-jun.Effect of fuzheng paidu pian on the changes of CD4+T Lymphocytes in early infective phase of asymptomatic human immunodeficiency virus[J].Journal of Clinical Rehabilitative Tissue Engineering Research August 19,2007 Vol.No.33:6712-6716.
[47]郭会军,郭玉明,刘学伟.中医药对32例无症状HIV感染者早期干预的临床观察[C].中华中医药学会防治艾滋病学术研讨会暨2007年年会,2007,11,224-226.
[48]彭勃,郭会军,刘学伟.中医不同治法对166例无症状人类免疫缺陷病毒感染者CD4+T淋巴细胞的影响[J].中医杂志,2008,49(2)：142-143.
[49]郭会军,陈继忠,郭玉明.扶正排毒颗粒对32例艾滋病无症状者早期干预观察[J].中国中医药现代远程教育,2008,6(6)：528-529.
[50]王丹妮,郭会军,李华伟,等.扶正排毒片Ⅱ号治疗无症状HIV感染65例疗效观察[J].中华中医药杂志,2009,24(3)：385-388.
[51]李华伟.论艾滋病慢性进展期中医药治疗[J].中医学报,2010,(4)：6-7.
[52]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南[J].中华传染病志,2005,24(2)：133-144.
[53]李太生,王爱霞,邱志峰.艾滋病的免疫发病机制和免疫重建[J].中华医学杂志,2001,81(5)：310-313.
[54]Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy[J]. Nat Med.1999,5(5):512-7.
[55]Sedaghat AR, Siliciano RF, Wilke CO.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART[J].BMC Infect Dis.2008,(2):2.
[56]罗玲,李太生HIV/AIDS研究承载新知继续前行[N]..中国医学论坛报,2009-1-15,A9-A10.
[57]Donald L.Sodora,Guido Silvestri.Immune activation and AIDS pathogenesis[J]. AIDS,2008, (22):439-446.
[58]BRAUNWALD FAUCI,KASPER HAUSER,LONGO JAMESON王德炳主译.哈里森内科学(第十五版)[M].,北京：人民卫生出版社,2003,2280,2293.
[59]Fransje A. Koning, Sigrid A. Otto, Mette D. Hazenberg,et al. Low-Level CD4 Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection[J].The Journal of Immunology.2005,(175): 6117-6122.
[60]Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency[J].J Acquir Immune Defic Syndr Hum Retrovirol.1998,18(4):332-40.
[61]Mette D. Hazenberg; Sigrid A. Otto; Birgit H. B. van Benthem; Marijke Th. L. Roos; Roel A. Coutinho; Joep M. A. Lange; Dorte Hamann; Maria Prins; Frank Miedema.Persistent immune activation in HIV-1 infection is associated with progression to AIDS[J].AIDS.2003,17(13):1881-1888.
[62]Vajpayee M, Kaushik S, Sreenivas V, Mojumdar K, Mendiratta S, Chauhan NK. Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients[J]. Eur J Clin Microbiol Infect Dis. 2009,28(1):69-73.
[63]John J. Zaunders, Mee Ling Munier, Daniel E. Kaufmann, Susanna Ip, Pat Grey,et al. Early proliferation of CCR5 CD38 antigen-specific CD4_ Thl effector cells during primary HIV-1 infection.Blood. 2005,106:1660-1667
[64]ThomasW. McCloskey, Saroj Bakshi, Soe Than, et al.Immuno phenotypic Analysis of Peripheral Blooc Mononuclear Cells Undergoing In Vitro Apoptosis After Isolation From Human Immunodeficiency Virus-Infected Children[J].Blood.1998,92(11):4230-4237.
[65]Soe Than,Monica Kharbanda,Vivek Chitnis,et al.Clonal Dominance Patterns of CD8 T Cells in Relation to Disease Progression in HIV-Infected Children[J].The Journal of Immunology.1999,162:3680-3686.
[66]Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions[J].Nat Immunol.2003,(4):49-54.
[67]Ascher MS, Sheppard HW. AIDS as immune system activation:a model for pathogenesis. Clin Exp Immunol.1988,73:165-167.
[68]Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB,et al. Immune activation set point during early HIV infection predicts subsequent CD4R T-cell changes independent of viral load[J]. Blood. 2004,104:942-947.
[69]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究[J].中国实用内科杂志,2007,27(11)：847-850.
[70]Shailesh K. Choudhary,Nienke Vrisekoop,Christine A. Jansen,et al.Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease[J]. JOURNAL OF VIROLOGY.2007,(8):8838-8842.
[71]ZHANG Zi-ning, SHANG Hong, JIANG Yong-jun, LIU Jing, DAI Di, DIAO Ying-ying, GENG Wen-qing, JIN Xin and WANG Ya-nan.Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients[J]. Chin Med J.2006; 119(23):1966-1971.
[72]Steven G. Deeks, Christina M. R. Kitchen, Lea Liu, et al.Immune activation set point during early HIV infection predicts subsequent CD4Tcell changes independent of viral load[J]. Blood.2004,104:942-947.
[73]Ana E. Sousa, Jorge Carneiro, Martin Meier-Schellersheim, et al.CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load[J]. The Journal of Immunology.2002,169:3400-3406.
[74]Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, Moroni M, Clerici M, Gori A.Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics[J]. AIDS. 2004,18(2):211-216.
[75]Por Manuel Crespo, Isabel Caragol, Vicenc Falco, Esteban Ribera, Susana Urban, Albert Pahissa. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART[J].Enferm Infecc Microbiol Clin.2008,26:27-31.
[76]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察[J].国外医学中医中药分册.1996,18(1)：9-11.
[77]黄世敬,危剑安.中医治疗十年以上21例艾滋病病例报告[J].中国医药学报,2004,19(12)：731-732.
[78]吴维萍,朱琳,聂勇,郭长河.灭艾灵汤剂治疗早中期艾滋病70例[J].中医研究,2004,17(6)：30.
[79]王融冰,王晓静,王玉光.健脾益气法治疗艾滋病38例临床观察[J].北京中医.2007,26(1)：9-11.
[80]谢世平,潘万旗,郭会军,等。爱康胶囊对HIV/AIDS患者免疫功能影响的研究[J].辽宁中医杂志.2008,35(2)：165-167.
[81]河南省中医药治疗艾滋病临床专家组.益艾康胶囊对379例无症状期感染者的干预[J].中医研究.2008,21(3)：31-33.
[82]赵红心,张福杰.中西医结合治疗艾滋病的机遇与挑战[J].中国艾滋病性病.2008,14(4)：425-428.
[83]MosmannTR, CherwinskiH, Bond MW, etal.Two type of murinehelPer T cell clones.Definition according to Profiles of lymPhokine ac-tivities and secreted Proteins[J].J Immunol,1986,136:2348-2363.
[84]白雪帆,张树林.艾滋病的诊断与治疗[M].北京：人民军医出版社,2000：99-101.
[85]曹岩,刘红,卢晟晔,等。儿童肺炎支原体肺炎血清中TNF-a、IL-6、IL-8和IL-10浓度测定及其临床意义的研究[J],中国妇幼保健杂志2008,23(18)2575-2577
[86]Gfiffths CEM,Voor hees JJ,Nickoloff BJ. Characterization of intercellar adhesion molecular-1 and HLA-DR expression in normal and inflamed skin:modulation by recombinant interferon and tum-or necrosis factor [J]. Am Acad Deratol,1989,20:617-622.
[87]王胜奇,李春盛.新蝶呤在感染性疾病诊断中的作用[J].感染.炎症.修复.2008：12-20
[88]吴伯平,陆寿康.中医中药治疗爱滋病的探索性意见[J].北京中医杂志,1986,1：14-16.
[89]薛伯寿.从中医理论谈对艾滋病的认识[J].中医杂志,1991,32(1)：20-22.
[90]尤松鑫.艾滋病中医证治概述[J].江苏中医,1999,20(3)：3-5.
[91]孙利民,危剑安,黄霞珍,等.从中医理论谈艾滋病的发病机制[J].中华中医药杂志,2005,20(2)：100-101.
[92]孟澍江.温病学[M].上海科学技术出版社,1985.6-14.
[93]徐莲芝.实用艾滋病防治指南[M].天津科学技术出版社,2001,1：459.
[94]楼孝惠,陈智,黄茵,等.慢性乙型肝炎中医证型IL-2、IL-10、IL-12、IFN-γ水平的关系初探[J].中西医结合肝病杂志,2001,11(5)：282-283.
[95]周小军,孙克伟.慢性乙型病毒性肝炎患者Th1、Th2细胞因子与中医证型之关系[J].湖北中医杂志,2005,27(1)：17-18.
[96]王芹.扶正抗艾方”对HIV/AIDS患者IL-2及IFN-γ影响的研究[D].湖北中医学院硕士论文,2009-05-10.
[97]邓家驹.论中医免疫医学思想及其物质基础[J].中国中医基础医学杂志,1999,5(11)：22-23.
[98]侯安继,刘源.中医药治疗艾滋病研究进展[J].北京中医药大学学报,2003,10(1)：60-62.
[99]Watanabe K.传统汉方方剂对艾滋病病毒感染的病人外周单核类细胞在体外的免疫调节作用[J].国外医学：中医中药分册,1991,13(3)：14-18.
[100]张志军.小柴胡汤提取剂对感染细胞吞噬作用[J].国外医学：中医中药分册,1995,17(1)：64.
[101]王健,许建阳.中医药治疗艾滋病的现状及前景[J].武警医学,2003,4(10)：285-288.
[102]李延斌.六味地黄丸的新功效[J].江苏卫生保健,2004,(4)：21.
[103]李国勤.中医药治疗艾滋病呼吸道感染的临床观察[J].中医杂志,1993,(12)：671.
[104]张永祥,刘颖,王健.154例HIV/AIDS患者T细胞亚群检测结果分析[J].中国艾滋病性病,2004,10(6)： 463-464.
[105]刘静,张旻,张子宁.艾滋病病毒感染者淋巴细胞总数和CD4阳性T淋巴细胞数相关性的研究[J].中华检验医学杂志,2004,27(3)：156-158.
[106]李莉,魏飞力.HIV1感染者体内自然杀伤T细胞和免疫抑制性T细胞的变化[J].中国抗感染化疗杂志2003,3(6)：328-331.
[107]周华英HAART和H IV感染的免疫重建[J].国外医学免疫学分册,2005,28(5)：270-274.
[108]秦卫兵.TH1和TH2细胞在体内的分化[J].国外医学,免疫学分册,2002,25(1)：42-44.
[109]JayA. Levy,杨月.HIV的致病机理与细胞因子相关的病毒学及免疫学特性(下)[J].传染病网络动态,2004,12,31-32.
[110]张兴权,范江主编.艾滋病毒感染与艾滋病[M].第一版.北京：人民卫生出版社,2001：124
[111]张旻,尚红,张远志.新疆、辽宁地区HIV1感染者细胞因子特征研究[J].中国免疫学杂志,2003,19(6)：418-420.
[112]彭勃,苗明三,郭会军,等.扶正排毒片干预环磷酰氨致免疫抑制小鼠免疫功能的效应[J].中国临床康复,2006：10(43)：126-128.
[113]彭勃,苗明三,郭会军,等.扶正排毒片对轻化可的松致免疫抑制小鼠免疫功能的调节[J].中国临床康复,2006：10(39)：141-143.
[114]李伟,彭勃,刘景超,等.扶正排毒片水提取物抑制HIV-1病毒活性的实验研究[J].河南中医学院学报,2007,22(5)：1-5.
[115]张娴,力曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20-22.
[116]吕圭源,李万里,刘明哲.白术抗衰老作用研究[J].中国现代应用药学,1996,13(5)：26-29.
[117]张萍,祝希娴.甘草及其制剂药理与临床应用研究新进展[J].中草药,1997,28(9)：568.
[118]李铁民,梁再赋.甘草提取物及其衍生物的抗病毒研究现状[J].中草药,1994,25(12)：655.
[119]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究[J].中国实用内科杂志,2007,27(11)：847-850.
[120]苏立稳.试论获得性免疫缺陷综合征得中医病机[J].陕西中医,1994,15(4)：164.
[121]鲍作义,李林,庄道民,等.HIV感染者CD4/CD8细胞与病毒载量的关系[J].中国公共卫生,2003,19(11)：1380-1381.
[122]姚均,何忠平,张建平.应用流式细胞仪研究HIVAIDS患者的免疫状况[J].临床输血与检验,2002,4(1)：9-11.
[123]袁伟杰,郭峰.细胞因子与肾小球肾炎[J].上海免疫学杂志,1992,12(2)：191-192.
[124]漆以芹.消化性溃疡病患者治疗前后血清GM-CSF、IL-8和IL-6水平检测的临床意义[J].中国临床实用医学,2009,3(12)93-94.
[125]曹岩,刘红,卢晟晔,等.儿童肺炎支原体肺炎血清中TNF-a、IL-6、IL-8和IL-10浓度测定及其临床意义的研究[J].中国妇幼保健杂志,2008,23(18)：2575-2577.
[126]黄雪涛.细胞因子与疾病的治疗[J].中国免疫学杂志,1994,2：129.
[127]Kim JM,Oh YK.Kim YJ, et al.Polarized secretion of CXC chemokines by human intestinal epithelial cells in response to Bacteroides fragilis enterotoxin:NF-kappa B plays a major role in the regulation of IL-8 expression[J].Clin Exp lmmunol,2001,123(3):421-427.
[128]Nanthakumar NN, Fusunyan RD, Sanderson I, et al. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis[J].Proc Natl Acad SciUSA.2000,97(11): 6043-6048.
[129]陈克敏.细胞因子与肾炎[J].国外医学免疫学分册,1992,1(2)：75-76.
[130]董林,李明,张元英.肺炎支原体肺炎患儿细胞因子测定的探讨[J].放射免疫学杂志,2002,15(1)：1-2.
[131]闫柏刚.严重刨伤后新蝶呤/生物蝶呤的变化及意义[J].国外医学·临床生物化学与检验学分册.1999,20(3)：122-123.
[132]岑玉文HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究[D].广州中医药大学博士论文,2008-04-01
[133]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1)：8-17.
[134]Chung KF.C ytokines in chronic obstructive pulmonary disease[J].EurRespir,2001,18:50-59.
[135]王胜,徐风珍,陈余清.慢性阻塞性肺疾病痰液白细胞介素8、6和肿瘤坏死因子测定及其意义[J].中华结核和呼吸杂志,2000,23：465467.
[1]尤松鑫.艾滋病中医证治概述[J].江苏中医,1997,20(3)：3-5.
[2]黄炳山.中医治疗艾滋病[M].哈尔滨：黑龙江科学技术出版社,1990,25.
[3]彭勃,刘爱华,谢世平.艾滋病中医病病机及发病途径之思考[C].中华中医药学会防治艾滋病学术研讨会暨2006年年会,2006年12月,26.
[4]苏诚炼.中医药试治艾滋病30例临床报告[J].中医杂志,1990,31(3)：27.
[5]蒋心悦.浅谈艾滋病的病因病机[J].中国医药学报,2001,16(6).
[6]陈瑀.卫气浅谈——艾滋病辨病探索[J].中国中医基础医学杂志,2002,8(4)：11.
[7]侯安继,刘源.中医药治疗艾滋病研究进展[J].北京中医药大学学报,2003,10(1)：60-62.
[8]向楠,李晓东.中医药治疗艾滋病研究进展[J].湖北中医学院学报,2004,6(4)：92-93.
[9]杨凤珍,烟建华,王健.艾滋病元气损伤病机的研究[J].中国中医基础医学杂志,2005,11(2)：147-148下转138.
[10]黄碧群,朱镇华证素概念的辨析[J].中华中医药杂志,2005,20(5)：273-274.
[11]溥敏敏中医“证素”研究[J].时珍国医国药,2008,19(6)：1490-1450.
[12]马斌,高颖.中风病恢复期证候要素的研究[J].江苏中医药,2007,39(1)：27.
[13]马斌,高颖.中风病发病第7天和第14天证候要素演变规律初步研究[J].辽宁中医杂志.2006,33(12)：1561.
[14]张启明,王永炎,张志斌,等.外感病因中证候要素的提取[J].山东中医药大学学报,2005,29(5)：339.
[15]彭勃,谢世平,苏春娅,等.艾滋病中医辨证方法探析[C],2004年中华中医药学会年会论文集,28.
[16]方路,王莉,段呈玉,等.云南省180例HIV/AIDS的中医症状及证候的初步分析[J].云南中医中药杂志,2006,27(3)：40-41.
[17]谢世平,潘万旗,梁慕华.艾滋病中医基本证型的相关文献分析[J].河南中医学院学报,2006,21(122)：6-8.
[18]杨凤珍,烟建华,王健,等HIV/AIDS中医分期辨证治疗[J].中国医药学报.2004,19(4)：240-242..
[19]5省中医药治疗艾滋病项目临床技术培训资料.国家中管局.2004,8.
[20]黄世敬,危剑安.中医治疗十年以上21例艾滋病病例报告[J].中国医药学报,2004,19(12)：731-732.
[21]李国勤.艾滋病中医辨治体会[J].江苏中医.1994,15(2).
[22]王宝祥,石昌德,董雪梅.中医药抗艾滋病的临床研究[J].空军医高专报.1998,20(1)
[23]崔述贵等.艾滋病的辨证论治探微.中医函授通讯.1994,13(5)：32-35
[24]秦国政,李庆生,张春和,等.艾滋病中医发病学特点及中医证候数据库建立研究简报[J].云南中医学院学报,2008,31(2)：43-45
[25]杨凤珍,王健,赵敏,等.72例HIV/AIDS患者中医证候与T淋巴细胞亚群和病毒载量相关性研究[J].中国医药学报,2004,19(12)：733-737.
[26]黎耘,周正质.中医药防治艾滋病的研究现状与前景展望[J].天然产物研究与开发,2003,15(3)：273-276.
[27]王朝霞,宋丽君.甘草甜素的研究现状[J].中国中西医结合杂志,2002,22(10)：796-798.
[28]王家骅,王晓光.中药抗癌抗艾滋病作用[J].时珍国医国药,2000,11(3)：276-277.
[29]严启新,罗天浩.苦瓜的研究与开发思考[J].时珍国药研究,1997,8(4)：380-380.
[30]李庆宪,侯安继.中药治疗艾滋病的研究进展[J].时珍国医国药,2003,14(7)421-423.
[31]赵晶,张致平,陈鸿珊,等.黄芩甙元及其苄基衍生物的制备与抗人免疫缺陷病毒实验研究[J].药学学报1997,32(2)：140-143.
[32]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(11)：20-22.
[33]蔡德,佘白蓉,杨绮华.淫羊藿总黄酮提取及其含量测定[J].广东药学院学报,2005,21(1)：75-76.
[34]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000.7(1)20-22.
[35]张志军.艾滋病与汉方[J].国外医学中医中药分册,1995,17(3)：11-13.
[36]吴维萍,朱琳,聂勇.灭艾灵汤剂治疗早中期艾滋病70例[J].中医研究,2004,17(6)：30
[37]张永祥,温瑞兴,关崇芬.中研Ⅰ号、中研Ⅱ号和艾通冲剂对HIV/AIDS患者病毒载量与免疫功能作用的观察[J].中国中医基础医学杂志,2004,10(8)：41-42.
[38]徐淑玲,吴小娴.扶正祛邪中药复方对猴艾滋病模型实验研究[J].中国实验方剂学杂志,2003,9(1)：42-44.
[39]张其威,张楚瑜.抗病毒中药研究的最新进展[J].中成药,2005,27(1)：116-119.
[40]作者无.我国抗艾滋病中药在泰国上市[J].中医药国际参考,2008,1：24-25.
[41]张永容,苏斌练.抗艾滋病药物“中药2号”复方的初步研究[J].医学研究通讯,1998,27(11)：37-39.
[42]关崇芬,王健,徐淑玲.中研2号治疗HIV/AIDS的临床和实验研究[J].中国中西医结合杂志,2003,23(7)：494-497.
[43]韩桂华.中医药治疗艾滋病60例临床观察[J].中医杂志2004,45(7)：515-516.
[44]孟坤.喘可治一种多功能的免疫调节剂在艾滋病上的临床应用研究[A].2004年年会及防治艾滋病培训会议资料[C].郑州：2004,31.
[45]兰金初,李德益.三归片治疗艾滋病临床研究[J].河南中医学院学报,2005,20(1)：11-12
[46]吕维柏.新世纪康保治疗43例艾滋病人的临床报告[J].中国中西医结合杂志,2003,23(7)：494-497.
[47]吕维柏.金龙胶囊治疗感染者20例初步报告[J].中国艾滋病性病,2004,10(1)：18-19.
[48]吴昊.唐草片治疗HIV/AIDS的临床研究[A].中医药治疗艾滋病的研究进展[C].北京：中医古籍出版社,2004,4：103.
[49]张可.金黄胶囊(金黄口服液)治疗/10例分析[A].第一届全国中西医结合防治艾滋病学术研讨会论文汇编[C].北京：2003,4：59.
[50]田圣志.爱可扶正片治疗艾滋病99例临床疗效分析[A].中国艾滋病药物治疗研讨会资料汇编[C],2001,9：160-166.
[51]王丹妮.非药物疗法在艾滋病治疗中的运用[A].中华中医药学会防治艾滋病国际学术研讨会论文集[C],郑州：2007-11-24.
[52]王丹妮.非药物疗法在艾滋病治疗中的运用[J].中国医药指南,2007,9：118-120.
[53]舒钟民.实用非药物疗法大全[M].北京：中国古籍出版社,1999：3.
[54]蔡德英.浅析非药物疗法与针灸治疗[J].中国中医药信息杂志,2005.(12)12：5-6.
[55]尹勇,段丽萍,刘玉生.针灸治疗艾滋病23例[J].上海中医药大学学报,2002,16(2)：29-30.
[56]刘继明.针刺与耳针治疗24例艾滋病患者临床观察[J].针灸临床杂志,1999(15)1：24-25.
[57]王健.艾滋病的中医辨证论治初探[J].贵阳中医学院学报,1995,(4)：1.
[58]M.D. Smith. abstract.Presented at World Conress of Acupun and Natural Med.Beijing 1987:11.
[59]墨西哥AIDS治疗中心.中医药治疗艾滋病效果好[J].中医药动态,1989,(7)：51.
[60]M.Goh et al.Amer J.Acupun.1992;(4):361.
[61]韦玲.针刺治疗艾滋病并发周围神经病变的临床观察[J].中国针灸,2003,23(1)：9-10.
[62]吴欣.针灸治疗艾滋病并发带状疱疹43例[J].江苏中医,2002,10：431.
[63]杨甲三,曹一鸣.腧穴学[M].上海：上海科学技术出版社,1984：189-190.
[64]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[65]李崇忠,李静.中医药治疗艾滋病理论的建立与临证应用[J].实用中医内科杂志,2002,16(2)：62-65.
[66]赵丹,李峰,张宁.中医非药物疗法防治艾滋病研究进展[J].北京中医药大学学报,2006,29(1)：63-66.
[67]王磊.艾灸疗法作用机理国内外研究进展[J].中国针灸,2001,21(9)：567-570.
[68]江苏新医学院.中药大辞典·上册[M]上海：上海科学技术出版社,1986：560.
[69]王融冰.中医药治疗艾滋病的研究概况[J].继续医学教育,2006,20(19)：67-73.
[70]方旭.艾滋病的中医饮食疗法[J].东方食疗与保健,2006,1(23).
[71]俞福康译.双足与保健[J].2003年第2期.
[72]王明辉.重视艾滋病的中医药治疗[J].专家讲坛,2003,2(10).
[73]张妍玲.双黄连粉针剂治疗艾滋病的临床观察[J].山西医科大学学报,1999,30(2)：177-179.
[74]彭勃,王丹妮.对艾滋病无症状HIV感染期的认识[J].中华中医药杂志,2006,21(11)：663-665.
[75]郭会军,王丹妮.探析无症状HIV感染期持续时间[J].中国中医基础医学杂志,2007,13(1)：62-63.
[76]王丹妮,彭勃,郭会军,李华伟.艾滋病无症状HIV感染期称谓的探讨与建议[J].中华中医药杂志,2010,25(4)：520-523.
[77]彭勃,王丹妮.中医药治疗无症状HIV感染期探析[J].山东中医杂志,2006.25(7)：446-447.
[78]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的关键切入点[J].浙江中医杂志,2006,41(10)：571-572.
[79]郭会军,王丹妮,刘学伟.中医药治疗艾滋病应重视对无症状HIV感染期的早期干预[J].上海中医药杂志,2006,40(7)：17-18.
[80]彭勃,王丹妮.无症状HIV感染期是中医药治疗艾滋病的黄金切入点[J].中国临床康复,2006,10(19)：166-167.
[81]彭勃,李华伟.中医药治疗艾滋病的实践与思考[J].江苏中医药,2006,27(4)：4-7.
[82]彭勃.研究艾滋病要念好三字经[J].中国中医药报.2005年12月16日
[83]彭勃,李华伟.中医药治疗获得性免疫缺陷综合征的思路和切入点[J].中医杂志.2006；47(6)：412-413.
[84]彭勃,王丹妮.无症状HIV感染期持续时间研究.中华中医药学会防治艾滋病学术研讨会暨2006年年会论文集[C]广州：2006,12：1-4.
[85]郭会军,王丹妮.论中医药治疗艾滋病的研究方向.中国医药指南,2007,9(9)：116-118
[86]王丹妮,彭勃,郭会军.中医药治疗艾滋病疗效评价探析[J].中国中医基础医学杂志,2010,16(12)：1102-1103.
[87]Levin J S, Glass T A. Kushi L H, et al. Quantitative methods in research on complementary and alternative medicine. A methodological manifesto [S]. Med Care,1997,35(11):1079.
[88]吕维柏,王健,关崇芬.中医药治疗艾滋病的研究进展[M].北京：中国古籍出版社,2004,87-95.
[89]郭会军,刘学伟,王丹妮.扶正排毒片对艾滋病无症状期的疗效观察[J].上海中医药杂志,2006,40(1)：20-21.
[90]郭会军,刘学伟,王丹妮.爱康Ⅱ治疗艾滋病相关综合征疗效观察[J].河南中医学院学报,2005,20(6)：6-7.
[91]高洪才,李幼平,张伯礼.中医药临床疗效评价实践中的几点思考[J].天津中医药,2007,24(4)：275-276.
[92]王健,刘颖.关于中医药治疗艾滋病疗效评价的认识与思考[J].河南中医学院学报,2006,21(6)：6-8.
[93]鞠鹏,罗士德.对中药治疗艾滋病疗效评价体系的儿点看法[J].河南中医学院学报,2007,22(2)：1-2.
[94]张健,王沛.生存质量和中医整体观在肿瘤疗效评价中的意义[J].中医药管理杂志,2007,15(1)：56-58.
[95]刘建平.循证中医药临床研究方法学[M].北京：人民卫生出版社,2006,前言.
[96]梁润英,谢世平,闫国立.中医药治疗艾滋病临床文献质量评价[J].中医研究,2008,21(3)：34-36.
[97]曾毅.警惕艾滋病[M].第1版.清华大学出版社北京：2005.65.
[98]何建凡,冯铁建,李良成,等.HIV感染者的免疫学功能变化及其与病程发展的关系[J].中国性病艾滋病防治,2001,7(1)：1-4.
[99]王丹妮,郭会军,李华伟.扶正排毒片Ⅱ号治疗无症状HIV感染者65例疗效观察[J].中华中医药杂志,2009,24(3)：385-388.
[100]张伯礼,康立源,项耀祖.中药新药临床试验中有关疗效评价若干问题的思考[J].中药新药与临床杂志,2007,26(11)：861-863.
[101]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南.中华传染病志,2005,24(2)：133-144.
[102]李太生,王爱霞,邱志峰.艾滋病的免疫发病机制和免疫重建.中华医学杂志,2001,81(5)：310-313.
[103]Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med.1999,5(5):512-7.
[104]Sedaghat AR, Siliciano RF, Wilke CO.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.BMC Infect Dis.2008,(2):2.
[105]罗玲,李太生HIV/AIDS研究承载新知继续前行.中国医学论坛报,2009-1-15,A9-A10.[106]Donald L.Sodora,Guido Silvestri.Immune activation and AIDS pathogenesis. AIDS,2008, (22):439-446.
[107]BRAUNWALD FAUCI,KASPER HAUSER,LONGO JAMESON王德炳主译.哈里森内科学(第十五版),北京：人民卫生出版社,2003,2280,2293.
[108]Fransje A. Koning, Sigrid A. Otto, Mette D. Hazenberg,et al. Low-Level CD4 Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection.The Journal of Immunology.2005,(175):6117-6122.
[109]Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol.1998,18(4):332-40.
[110]Mette D. Hazenberg; Sigrid A. Otto; Birgit H. B. van Benthem; Marijke Th. L. Roos; Roel A. Coutinho; Joep M. A. Lange; Dorte Hamann; Maria Prins; Frank Miedema.Persistent immune activation in HIV-1 infection is associated with progression to AIDS.AIDS.2003,17(13):1881-1888.
[111]Vajpayee M, Kaushik S, Sreenivas V, Mojumdar K, Mendiratta S, Chauhan NK. Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients. Eur J Clin Microbiol Infect Dis.2009,28(1):69-73.
[112]John J. Zaunders, Mee Ling Munier, Daniel E. Kaufmann, Susanna Ip, Pat Grey,et al. Early proliferation of CCR5 CD38 antigen-specific CD4_ Thl effector cells during primary HIV-1 infection.Blood. 2005,106:1660-1667
[113]ThomasW. McCloskey, Saroj Bakshi, Soe Than, et al.Immuno phenotypic Analysis of Peripheral Blood Mononuclear Cells Undergoing In Vitro Apoptosis After Isolation From Human Immunodeficiency Virus-Infected Children. Blood. 1998,92(11):4230-4237.
[114]Soe Than,Monica Kharbanda,Vivek Chitnis,et al.Clonal Dominance Patterns of CD8 T Cells in Relation to Disease Progression in HIV-Infected Children. The Journal of Immunology.1999,162:3680-3686.
[115]Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol.2003,(4):49-54.
[116]Ascher MS, Sheppard HW. AIDS as immune system activation:a model for pathogenesis. Clin Exp Immunol.1988,73:165-167.
[117]Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB,et al. Immune activation set point during early HIV infection predicts subsequent CD4R T-cell changes independent of viral load. Blood. 2004,104:942-947.
[118]韩扬,邱志峰,李太生,等.人类免疫缺陷病毒感染者及艾滋病患CD8+CD38+、CD8+HLA-DR+比例与HIV载量的相关性研究.中国实用内科杂志,2007,27(11)：847-850.
[119]Shailesh K. Choudhary,Nienke Vrisekoop,Christine A. Jansen.et al.Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease. JOURNAL OF VIROLOGY.2007,(8):8838-8842.
[120]ZHANG Zi-ning, SHANG Hong, JIANG Yong-jun, LIU Jing, DAI Di, DIAO Ying-ying, GENG Wen-qing, JIN Xin and WANG Ya-nan.Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients. Chin Med J.2006; 119(23):1966-1971.
[121]Steven G. Deeks, Christina M. R. Kitchen, Lea Liu, et al.Immune activation set point during early HIV infection predicts subsequent CD4Tcell changes independent of viral load. Blood.2004,104:942-947.
[122]Ana E. Sousa, Jorge Carneiro, Martin Meier-Schellersheim, et al.CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load. The Journal of Immunology.2002,169:3400-3406.
[123]Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, Moroni M, Clerici M, Gori A.Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS. 2004,18(2):211-216.
[124]Por Manuel Crespo, Isabel Caragol, Vicenc Falco, Esteban Ribera, Susana Urban, Albert Pahissa. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.Enferm Infecc Microbiol Clin.2008,26:27-31.
[125]赵晓梅,吕维柏.中医药治疗531例HIV感染者的临床观察.国外医学中医中药分册.1996,18(1)：9-11.
[126]吴维萍,朱琳,聂勇,郭长河.灭艾灵汤剂治疗早中期艾滋病70例.中医研究,2004,17(6)：30.[127]王融冰,王晓静,王玉光.健脾益气法治疗艾滋病38例临床观察.北京中医.2007,26(1)：9-11.
[128]谢世平,潘万旗,郭会军,等。爱康胶囊对HIV/AIDS患者免疫功能影响的研究.辽宁中医杂志.2008,35(2)：165-167.
[129]河南省中医药治疗艾滋病临床专家组.益艾康胶囊对379例无症状期感染者的干预.中医研究.2008,21(3)：31-33.
[130]赵红心,张福杰.中西医结合治疗艾滋病的机遇与挑战.中国艾滋病性病.2008,14(4)：425-428.